Masimo (NASDAQ:MASI) Price Target Raised to $210.00

by · The Markets Daily

Masimo (NASDAQ:MASI – Free Report) had its target price upped by Piper Sandler from $180.00 to $210.00 in a research note published on Wednesday,Benzinga reports. They currently have an overweight rating on the medical equipment provider’s stock.

A number of other research analysts have also issued reports on MASI. Stifel Nicolaus restated a “buy” rating and set a $190.00 price target (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Raymond James upgraded Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 target price for the company in a research note on Wednesday, November 6th. Wells Fargo & Company increased their price objective on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. BTIG Research lifted their target price on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research report on Wednesday, November 6th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $175.67.

Check Out Our Latest Report on MASI

Masimo Stock Performance

Shares of MASI opened at $169.52 on Wednesday. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The firm has a market cap of $9.08 billion, a PE ratio of 116.91 and a beta of 1.01. Masimo has a 12 month low of $101.61 and a 12 month high of $180.97. The stock has a fifty day moving average price of $160.45 and a 200-day moving average price of $134.73.

Masimo (NASDAQ:MASI – Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $504.60 million during the quarter, compared to analysts’ expectations of $502.87 million. During the same period last year, the business posted $0.63 earnings per share. The firm’s revenue was up 5.4% compared to the same quarter last year. Equities research analysts predict that Masimo will post 4.03 earnings per share for the current fiscal year.

Institutional Trading of Masimo

Several hedge funds and other institutional investors have recently bought and sold shares of MASI. FMR LLC lifted its holdings in Masimo by 41.2% in the third quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock valued at $900,860,000 after acquiring an additional 1,970,883 shares during the period. Thrivent Financial for Lutherans boosted its holdings in Masimo by 42.1% during the second quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock worth $153,314,000 after buying an additional 360,497 shares in the last quarter. Point72 Asset Management L.P. grew its position in Masimo by 107.8% during the second quarter. Point72 Asset Management L.P. now owns 677,677 shares of the medical equipment provider’s stock valued at $85,347,000 after buying an additional 351,523 shares during the period. Westfield Capital Management Co. LP increased its holdings in Masimo by 23.2% in the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock valued at $185,869,000 after buying an additional 262,370 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Masimo by 45.9% in the second quarter. Dimensional Fund Advisors LP now owns 525,594 shares of the medical equipment provider’s stock worth $66,201,000 after acquiring an additional 165,257 shares during the period. 85.96% of the stock is owned by institutional investors and hedge funds.

About Masimo

(Get Free Report)

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

See Also